Pierre GOFFETTE, MD Pierre GOFFETTE, MD Interventional Radiology Cliniques Universitaires Saint- Luc Université catholique de Louvain Brussels TACE with DC beads as a TACE with DC beads as a pretransplant treatment for HCC pretransplant treatment for HCC Results with anatomopathological Results with anatomopathological data data Florence ET/ECIO 2008- Terumo/Biocompatible symposium
32
Embed
Pierre GOFFETTE, MD Interventional Radiology Cliniques Universitaires Saint-Luc Université catholique de Louvain Brussels TACE with DC beads as a pretransplant.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Pierre GOFFETTE, MDPierre GOFFETTE, MD Interventional Radiology
Cliniques Universitaires Saint-LucUniversité catholique de Louvain
Brussels
TACE with DC beads as a pretransplant TACE with DC beads as a pretransplant treatment for HCCtreatment for HCC
Results with anatomopathological dataResults with anatomopathological data
Bruix J.,Llovet J.M.: Prognostic Prediction and Treatment Strategy in Hepatocellular Carcinoma
Liver Transplantation for HCCLiver Transplantation for HCC5 year survival5 year survival
• Within Milan criteriaWithin Milan criteria >75%>75% Comparable to overall LTComparable to overall LT Waiting time < 6 MoWaiting time < 6 Mo Drop out % 10-20%Drop out % 10-20% No role for pre-LT adjuvant therapy(?)No role for pre-LT adjuvant therapy(?)
• Expanded criteriaExpanded criteria (USCF-Mount Sinaï)(USCF-Mount Sinaï) 25-44%25-44% (Single tum < 6.5cm or 3 tum < 4.5cm)(Single tum < 6.5cm or 3 tum < 4.5cm)
Belghiti J. Annals Surg Oncology 2008 Belghiti J. Annals Surg Oncology 2008
Liver Transplantation for HCCLiver Transplantation for HCC
• Rationale for TACERationale for TACE Bridge therapyBridge therapy
Control tumor + prevent progression, vasc. invasionControl tumor + prevent progression, vasc. invasion Neoadjuvant therapy to improve survivalNeoadjuvant therapy to improve survival
DownstagingDownstaging (to fullfil Milan criteria)(to fullfil Milan criteria)
Majno P. Ann Surg 1997, Graziadei I. Liver transpl. 2003 Majno P. Ann Surg 1997, Graziadei I. Liver transpl. 2003 Otto G. Liver Transpl. 2006Otto G. Liver Transpl. 2006
TACE before LTTACE before LTControversial UsefulnessControversial Usefulness
• Early stagesEarly stages Effective to prevent tumoral progressionEffective to prevent tumoral progression No influence on post-LT (disease-free) survivalNo influence on post-LT (disease-free) survival
Majno P. Ann Surg 1997, Oldhafer K. J. Hepatol 1998 , Graziadei I. L. Majno P. Ann Surg 1997, Oldhafer K. J. Hepatol 1998 , Graziadei I. L. transpl 2003, Maddala Y. L. transpl 2004, Decaens T. L. Transpl 2005transpl 2003, Maddala Y. L. transpl 2004, Decaens T. L. Transpl 2005Llovet J. Sem. Liver Dis 2006, Lesurtel M. Am J Transplantation 2006Llovet J. Sem. Liver Dis 2006, Lesurtel M. Am J Transplantation 2006
• Intermediate/Advanced stagesIntermediate/Advanced stages Effective downstaging ( > 50% red.) Effective downstaging ( > 50% red.) 35-45%35-45% Higher post-LT recurrence rateHigher post-LT recurrence rate Lower 5 yr survival (41 vs 83%)Lower 5 yr survival (41 vs 83%)
Majno, 1999Majno, 1999
HEPATOCELLULARCAHEPATOCELLULARCA
TACE before LTTACE before LT
DC Bead™ hydrogel microspheres are biocompatible, hydrophilic, non resorbable, and precisely calibrated spheres, able to load the doxorubicine.
Precise and controlled release of the chemotherapeutic agent into the tumor bed.
Drug Eluting BeadsDrug Eluting Beads(DC Beads, Biocompatible UK)
available sizesavailable sizes
RATIONALE TO USERATIONALE TO USE
Delivery of large amounts of drugs to tumors for a Delivery of large amounts of drugs to tumors for a prolonged timeprolonged time
Enhanced local tumor concentrationEnhanced local tumor concentration
Without incresead local toxicityWithout incresead local toxicity
Decreased serum level of chemotherapeutic agentDecreased serum level of chemotherapeutic agent
• 27 patients Child-Pugh A27 patients Child-Pugh A
• Response rate (CT at 6 month): 75%Response rate (CT at 6 month): 75%
• Liver abscesses 2, death 1Liver abscesses 2, death 1
• Median follow-up 28 monthsMedian follow-up 28 months
survival 1 year 92%survival 1 year 92% 2 year 89%2 year 89%
J Hepatology, 2007
J Hepatology, 2007
Serum doxorubicin pic value (5 min)Serum doxorubicin pic value (5 min) Conventional TACE : 890ng/mlConventional TACE : 890ng/ml
Precision TACE : 90ng/mlPrecision TACE : 90ng/ml
Brussels ExperienceBrussels ExperienceDrug Eluting Beads for HCC before LTDrug Eluting Beads for HCC before LT
• 88 withinwithin the Milan criteria• 1010 outsideoutside the Milan criteria
Diameter > 5cm Diameter > 5cm 11 > 3 tum < 3cm > 3 tum < 3cm 11 Multiple tum > 3cmMultiple tum > 3cm 88
Downstaging after TACE ?Downstaging after TACE ?
** overall 73 HCC pts treated by DC beads overall 73 HCC pts treated by DC beads over a 22 month periodover a 22 month period
Single center study: Single center study: 18*patients18*patients
LIVER TRANSPLANT CANDIDATES WITH HCCLIVER TRANSPLANT CANDIDATES WITH HCC CHARACTERISTICSCHARACTERISTICS
Sex, M/F 15/315/3
Age, years 47-73(58)47-73(58)
Etiology of CirrhosisEtiology of Cirrhosis
Ethyl
HCV (+ethyl 1)
HAV/HBV
NASH
Primary biliary cirrhosis
Non-cirrhotic HCC
99
33
22
22
1 1
11
Serum α-fetoprotein (ηg/mL) 4949 (4,5-3487)
Child-Pugh classification (A/B) 8/108/10
Child-Pugh score Mean 7,27,2 (5-9)
Materials and MethodsMaterials and MethodsHCC CharacteristicsHCC Characteristics
• Transplanted patients 12Transplanted patients 12 Delay: med 8.5 Mo (3-16)Delay: med 8.5 Mo (3-16) Biliary complications: 3Biliary complications: 3 Follow-up: med 8 monthFollow-up: med 8 month
1 recurrence at 4 mo ( < 50% nec)1 recurrence at 4 mo ( < 50% nec)
• Patients on waiting list Patients on waiting list 5 5 1 death (pneumonia)1 death (pneumonia)
• Complete necrosis of large tumors (> 5 cm)Complete necrosis of large tumors (> 5 cm)• µ-vascular permeation in 1 patientµ-vascular permeation in 1 patient• No inflammatory changes No inflammatory changes • Imaging for residual viable tumoral nodules Imaging for residual viable tumoral nodules
False (-)False (-) > untreated hypovascular tumor > untreated hypovascular tumor > very small viable nodules (delayed LT)> very small viable nodules (delayed LT)
Explanted SpecimenExplanted SpecimenHistological dataHistological data
52 yr old male, ethyl cirrhosis52 yr old male, ethyl cirrhosis5.2 cm right HCC - 2 cm left HCC5.2 cm right HCC - 2 cm left HCC
3 selective TACE – LT 2 Mo later3 selective TACE – LT 2 Mo later
52 yr old male, ethyl cirrhosis52 yr old male, ethyl cirrhosis5.2 cm right HCC (satellite nodules)-2 cm left HCC5.2 cm right HCC (satellite nodules)-2 cm left HCC
CONCLUSIONSCONCLUSIONS• Higher anti-tumoral response % if compared with
conventional TACE• Complete necrosis could be achieved even in
large HCC• TACE-related surgical complications mainly due
to Doxorubicin• Effective downstatging of most patients with
intermediate-advanced HCC• TACE with DCbeads could reduce the dropout %• Large prospective studies are needed
Drug Eluting Beads vs Microspheres before LTDrug Eluting Beads vs Microspheres before LTNicolini A.F. March 2008-SIR Annual meetingNicolini A.F. March 2008-SIR Annual meeting